Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Microsoft

Visa

Novartis, Visa, and Microsoft are three highly profitable businesses that generate excellent margins. These companies are also focused on growing and getting bigger over the years.

3 Unstoppable Stocks to Buy and Hold for Decades

The latest trading day saw Novartis (NVS) settling at $97.87, representing a -1.55% change from its previous close.

Novartis (NVS) Suffers a Larger Drop Than the General Market: Key Insights

Eli Lilly

McKesson

Although healthcare stocks lag other sectors, large-cap leaders such as  Eli Lilly & Co. NYSE: LLY, McKesson Corp. NYSE: MCK and Novartis AG NYSE: NVS  are in possible buy ranges as they get moving-average support.

Eli Lilly, McKesson, Novartis Flash Promising Chart Action

UK-based biotech firm AstronauTx has secured £48 million ($61 million) in a significant Series A funding round, marking a step towards developing treatments for Alzheimer's and other neurodegenerative diseases, according to the Financial Times. Spun out of University College London in 2019, the company initially focused on astrocytes, brain support cells crucial for neuron health.

Novartis leads funding round for UK Alzheimer's specialist

Novartis (NVS) closed at $97.14 in the latest trading session, marking a +1.03% move from the prior day.

Novartis (NVS) Ascends But Remains Behind Market: Some Facts to Note

Pfizer

AstraZeneca

Merck

Moderna

CRISPR Therapeutics

GlaxoSmithKline

Sanofi

Scientists Katalin Karikó and Drew Weissman were awarded the Nobel prize this week for a discovery that went under the radar for many years, until it was found to hold the key to stabilising mRNA vaccines used in the fight against the Covid-19 pandemic.   The researchers own the patents to the nucleoside modification technology licensed out to drug companies such as BioNTech SE, where Karikó once worked, which developed an mRNA vaccine against Covid-19 with Pfizer Inc (NYSE:PFE), and Moderna Therapeutics Inc (NASDAQ:MRNA).

Nobel for mRNA: Which other biotech stocks might be overlooked?

Sandoz Group AG

Ex-Sandoz, Novartis confirmed its yearly guidance and capital allocation priority (DPS growth and buyback). We believe NVS might experience a margin uplift following the spin-off. Sandoz started trading with a market cap of $11.2 billion. The company has now completed its business transformation. We expect positive pipeline readouts; however, Novartis's valuation looks full.

Novartis: Better Margin Visibility Ex-Sandoz

Basel, October 5, 2023 — Novartis will present new data from 29 Novartis and investigator-led abstracts at the European Society for Medical Oncology (ESMO) Congress 2023, highlighting latest developments from across its oncology portfolio and addressing unmet needs of patients diagnosed with some of the most prevalent cancers, including prostate and breast.

Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer

Swiss drug giant Novartis AG (ADR) (NYSE:NVS) has just completed the spin-off of Sandoz, its generics and biosimilars business. Kelloggs has done the same, hiving off its cereal business into WK Kellogg Co this week, and renaming the remaining snacks and frozen food business Kellanova.

Spin-outs on the rise as companies try to win out in desolate M&A market

Novartis (NVS) separates Sandoz into an independent company. The company reaffirms the previously provided guidance.

Novartis (NVS) Spins off Sandoz, Reiterates Annual Outlook

Sandoz (OTCMKT: SDZNY ) stock is a hot topic among traders on Wednesday as the company starts trading after a spinoff. Let's get into everything investors need to know about Sandoz below!

SDZNY Stock: 7 Things to Know as Novartis Spinoff Sandoz Starts Trading Today

Swiss drugs giant Novartis AG has completed the spin-off of its generics business Sandoz, which made an underpowered stock market debut. From an IPO price of 24 Swiss Francs, the stock drifted down to 23.82 Swiss Francs.

Novartis spin-off completed as Sandoz makes subdued start on Swiss bourse

Novartis has completed the planned spin-off of its generics and biosimilars business, Sandoz, which will begin trading on the SIX Swiss Exchange on Wednesday.

Novartis unit Sandoz set to start trading after completing spinoff

Novartis has completed the planned spin-off of its generics and biosimilars business Sandoz , the Swiss drugmaker said in a statement on Wednesday.

Novartis completes Sandoz spinoff

Basel, October 4, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today celebrates the start of share trading on the SIX Swiss Exchange as an independent company.

Sandoz enters new era as standalone global leader and European champion in generic and biosimilar medicines

Ad hoc announcement pursuant to Art. 53 LR  Novartis executes separation of the Sandoz business to create an independent company by way of a 100% Spin-off Shares of Sandoz will be listed and commence trading today on the SIX Swiss Exchange Spin-off allows shareholders to benefit from a Novartis with capital and management attention fully focused on innovative medicines Novartis pipeline one of the industry's most competitive, focused on key next-generation platforms and four core therapeutic areas Company reiterates guidance for FY 2023, with sales expected to grow high single digits and core operating income low double digits to mid-teens 1 Novartis to maintain consistent approach to capital allocation priorities including share buy-back and continued strong and growing dividend policy, with no re-basing after the Sandoz Spin-off Basel, October 4, 2023 — Novartis today completed the Spin-off of Sandoz, its Generics and Biosimilars business, through a dividend-in-kind distribution to holders of Novartis shares and American Depositary Receipts (ADRs), with each holder receiving one Sandoz share for every five Novartis shares or one Sandoz ADR for every five Novartis ADRs, held at the close of business on October 3, 2023.

Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company

Novartis' (NVS) phase III study on pipeline candidate iptacopan in patients with IgAN shows superiority versus placebo in proteinuria reduction.

Novartis (NVS) Announces Positive Data on Kidney Disease Drug

Novartis AG is considering selling a part of its radiopharmaceuticals business, Bloomberg News reported on Tuesday, citing people with knowledge of the matter.

Novartis considers selling radiopharma unit's assets - Bloomberg News

AbbVie

Amgen

Bristol-Myers

Johnson & Johnson

The lengthy negotiation process with Medicare won't end until August 2024, with reduced prices going into effect in January 2026.

Drugmakers opt in to Medicare drug price negotiations – here's what happens next

All the drugmakers that make the 10 prescription medicines subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen and Novartis , said they signed on to participate in the talks by the Oct. 1 deadline.

Drugmakers sign on to negotiate Medicare prices under protest

Ad hoc announcement pursuant to Art. 53 LR Phase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint, demonstrating superiority of iptacopan vs placebo in proteinuria reduction 1 Iptacopan is an investigational, first-in-class, oral factor B inhibitor targeting the alternative pathway of the complement system 2–4 IgAN is a complement-mediated kidney disease, affects mostly young adults, and is a major cause of chronic kidney disease and kidney failure worldwide 5–9 Novartis plans to review interim results with FDA to enable a potential regulatory submission for accelerated approval; study continues with final readout (24 months) in 2025 4 APPLAUSE-IgAN is the third positive Phase III trial for iptacopan and development program is ongoing across five indications; regulatory review is underway for paroxysmal nocturnal hemoglobinuria (PNH) in the US and EU 10,11 Basel, October 2, 2023 — Novartis today announced positive top-line results from the pre-specified interim analysis of the Phase III APPLAUSE-IgAN study (NCT04578834) at 9 months1.

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)

Basel, September 29th, 2023 — Novartis today announced that it has completed its divestment of ‘front of eye' ophthalmology assets to Bausch + Lomb, a global eye health company, in a transaction valued up to USD 2.5 billion, consisting of 1.75 billion in upfront cash, plus potential additional milestone payments.

Novartis completes divestment of ‘front of eye' ophthalmology assets

British American Tobacco

Diageo

SAP SE

TotalEnergies SE

It was nice while it lasted, but the AI-driven stock market rally is rapidly running out of gas.

The US Stock Market Could Crack in October: 6 ‘Strong Buy' European Dividend Aristocrats to Buy Now

Novartis' (NVS) Sandoz broadens its biosimilar portfolio with Tyruko's approval, a biosimilar of the multiple sclerosis drug Tysabri in the EU.

Novartis' (NVS) Sandoz Gets EC Nod for Tysabri's Biosimilar

Novartis' core EPS payout ratio is poised to come in at around 51% in 2023. The Swiss drugmaker grew at a solid clip in the first half of this year. The company enjoys an AA- credit rating from ratings agency S&P.

Novartis: Buy This Dividend Aristocrat For Consistent Income

News for Novartis Stock (NVS)